预约演示
更新于：2026-02-05
Insulin Degludec / Liraglutide
德谷胰岛素/利拉鲁肽
更新于：2026-02-05
概要
基本信息
药物类型 多肽激素 |
别名 IDegLira、Insulin degludec/Liraglutide、Insulin degludec/Victoza + [12] |
作用方式 激动剂 |
作用机制 GLP-1R激动剂(胰高血糖素样肽-1激动剂)、INSR激动剂(胰岛素受体激动剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2014-09-18), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 4857
当前序列信息引自: *****
Sequence Code 50953
当前序列信息引自: *****
Sequence Code 91440
当前序列信息引自: *****
关联
35
项与 德谷胰岛素/利拉鲁肽 相关的临床试验NCT06113341
A Multi-centre, Prospective, Single-arm, Non-interventional Study Describing the Use of the Dose Check App in People Living With Type 2 Diabetes Mellitus and Treated With IDegLira in a Real-world Setting in Italy
NCT06408532
The Evaluation of the Efficacy and Safety of Switching to Once-daily IDegLira in Patients With Type 2 Diabetes Receiving Premixed Insulin Therapy, a Multi-center, Randomized Control Trial
JPRN-UMIN000052156
Comparison of insulin degludec/liraglutide versus insulin degludec in multiple daily injection therapy on subjects with type 2 diabetes; time to reach target glycemic levels - Conparison of IDegLira vs IDeg in multiple daily injection therapy
100 项与 德谷胰岛素/利拉鲁肽 相关的临床结果
登录后查看更多信息
100 项与 德谷胰岛素/利拉鲁肽 相关的转化医学
登录后查看更多信息
100 项与 德谷胰岛素/利拉鲁肽 相关的专利（医药）
登录后查看更多信息
144
项与 德谷胰岛素/利拉鲁肽 相关的文献（医药）2025-09-11CURRENT DIABETES REVIEWS
Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Article
作者: Liu, Delong ; Yang, Zhiyong ; Su, Ning ; Zhang, Lina ; Bai, Lexie
Introduction::
Clinical trials indicate that IDegLira is effective in treating type 2 diabetes mellitus (T2DM). This study aims to assess the efficacy and safety of IDegLira in type 2 diabetes mellitus (T2DM) comprehensively.
Methods::
To identify relevant randomized controlled trials, we searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov. Risk Ratios (RR) and 95% Confidence Intervals (CI) were calculated using the Mantel-Haenszel approach for dichotomous outcomes. Mean Difference (MD) and 95% CI calculated by the inverse variance approach were applied to continuous outcomes.
Results::
Twelve randomized controlled trials involving 7628 participants were included in this study. Compared with control groups, IDegLira has a significant hypoglycemic effect in reducing hemoglobin A1c (MD = −0.66; 95% CI [−0.85, −0.47]; p < 0.00001), fasting plasma glucose (MD = −0.90; 95% CI [−1.40, −0.41]; p = 0.0003), self-measured plasma glucose (MD = −0.82; 95% CI [−1.22, −0.42]; p < 0.0001) and achieving the hemoglobin A1c level of < 7.0%(RR = 1.66; 95% CI [1.44, 1.92]; p < 0.00001) or < 6.5% (RR = 2.13; 95% CI [1.76, 2.57]; p < 0.00001). IDegLira outperforms insulin in achieving the target of HbA1c < 7.0 or < 6.5% without hypoglycemia and weight gain. Besides, IDegLira did not increase the incidence of adverse events and serious adverse events.
Discussion::
In this section, IDegLira's benefits on simultaneously achieving glycemic control, weight loss, and reduced hypoglycemia risk were summarized. The statistical results were carefully interpreted in conjunction with clinical concerns regarding T2DM complications, adverse effects, and cost-effectiveness differences. An expanded discussion was conducted on integrating individualized HbA1c goals as a dual endpoint, without increasing body weight or the risk of hypoglycemia. Finally, the limitations of the present study are indicated.
Conclusions::
IDegLira exhibits a favorable glycemic control effect and acceptable adverse effects in Type 2 Diabetes Mellitus (T2DM). Superior performance in the target glycemic control, particularly suitable for T2DM patients who do not reach the target hemoglobin A1c and have comorbid CVD or obesity.
2025-09-01DIABETOLOGIA
Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial
Article
作者: Gómez-Medina, Ana M ; Pertuz-Noriega, Carlos E ; Gómez-Quesada, Yaline ; Villamil-Castañeda, Lina P ; Muñoz-Velandia, Oscar M ; Chaim, Salma N ; Aschner, Pablo ; Yepes, Carlos A ; Henao-Carillo, Diana C
Abstract:
Aims/objective:
The aim of the study was to assess the safety profile (defined as the percentage of patients with at least one hypoglycaemic event [more than 15 min with glucose levels <3.0 mmol/l as documented by continuous glucose monitoring] in the first 4 weeks of follow-up) for insulin degludec/liraglutide (IDegLira) compared with multiple daily insulin injections (MDI) during the transition from hospital to an outpatient setting.
Methods:
The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes. The study evaluated the percentage of patients with at least one hypoglycaemic event, the hypoglycaemia event density, the time in range (TIR 3.8–10 mmol/l), the time below range (TBR <3.0 or <3.8 mmol/l), and other glycaemic management metrics measured by continuous glucose monitoring.
Results:
Sixty-four patients were included in the analysis (32 in each group). They had a baseline HbA1c of 103 ± 11.6 mmol/mol (11.6 ± 1.7%) and age of 58 ± 12.4 years (means ± SD). The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008). The TIR 3.8–10 mmol/l was higher in the IDegLira group (80.6% vs 69.7%; p=0.008). The findings were consistent regardless of baseline HbA1c.
Conclusions/interpretation:
IDegLira proved to be safer and more effective than MDI for individuals with type 2 diabetes who had suboptimal glycaemic control, aiding in their transition from hospital to outpatient care.
Trial registration:
Clinicaltrials.gov NCT05767255
Funding:
This research was funded by a grant from the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE).
Graphical Abstract:
2025-08-01DIABETES OBESITY & METABOLISM
What is the ‘real‐world’ experience with fixed‐ratio combination therapy (insulin +
GLP
‐1 receptor agonist) in routine clinical practice? Take‐home messages for clinicians regarding key outcomes
Review
作者: Frias, Juan Pablo
Abstract:
Aims:
The fixed‐ratio combinations (FRCs) of a basal insulin and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA), IDegLira (insulin degludec/liraglutide) and iGlarLixi (insulin glargine/lixisenatide), offer a once‐daily injectable treatment option for adults with type 2 diabetes (T2D), combining complementary mechanisms of action to target both fasting and postprandial hyperglycaemia. While randomized controlled trials have demonstrated their efficacy and safety, real‐world evidence (RWE) provides important insights into their effectiveness, tolerability and use across routine clinical practice.
Materials and Methods:
This is a narrative review of selected real‐world studies assessing the FRCs IDegLira and iGlarLixi in adults with T2D. Studies assessing the use of FRCs to intensify and simplify therapy, as well as their use in special populations such as older adults were reviewed and are summarized.
Results:
Among individuals inadequately controlled on oral antihyperglycaemic drugs (OADs), basal insulin ± OADs, or GLP‐1 RAs, initiation of FRC therapy consistently improved glycaemic outcomes, supported modest weight loss or stability, and was associated with a low risk of hypoglycaemia. FRCs have also been evaluated as a strategy for simplifying complex insulin regimens. Transitions from basal–bolus or premixed insulin to FRCs maintained or improved glycaemic control while reducing total daily insulin dose and injection burden.Evidence in special populations and clinical contexts further supports the utility of FRCs. In older adults, FRC use was associated with reductions in HbA1c and hypoglycaemia risk, along with improvements in treatment satisfaction and functional measures. During Ramadan fasting, iGlarLixi demonstrated favourable glycaemic control, low hypoglycaemia incidence, modest weight loss and high adherence. Studies assessing glycaemic control using continuous glucose monitoring showed improvements in time in range, reductions in time above range and stable time below range, indicating enhanced glycaemic stability without increased risk of hypoglycaemia.Two real‐world head‐to‐head studies comparing IDegLira and iGlarLixi found both FRCs to be effective and well tolerated. IDegLira was associated with greater weight loss and lower insulin dose requirements, while iGlarLixi showed advantages in postprandial glucose control. Both agents demonstrated significant improvements in HbA1c and low rates of hypoglycaemia.
Conclusions:
Collectively, these real‐world studies confirm that FRCs are effective, safe and patient‐centred treatment options for adults with T2D. Their simplified dosing, metabolic benefits and favourable safety profiles support their use for both therapy intensification and de‐intensification across a broad spectrum of clinical scenarios. These findings reinforce results from randomized controlled trials, providing further confidence in the role of FRCs in contemporary diabetes care.
57
项与 德谷胰岛素/利拉鲁肽 相关的新闻（医药）2026-01-30
2026-01-23
核酸药物临床研究
100 项与 德谷胰岛素/利拉鲁肽 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 欧盟 | 2014-09-18 | |
| 2型糖尿病 | 冰岛 | 2014-09-18 | |
| 2型糖尿病 | 列支敦士登 | 2014-09-18 | |
| 2型糖尿病 | 挪威 | 2014-09-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病 | 临床1期 | 德国 | 2009-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 175 | 鬱築構鹹襯網繭醖餘願(衊廠遞鏇憲齋遞積構積) = 簾糧鏇蓋艱鹹膚蓋艱構 壓淵簾憲憲廠選糧淵網 (餘廠築簾積醖襯廠淵獵, - 1.6 ~ - 1.0) 更多 | 积极 | 2024-05-08 | |||
临床3期 | 145 | (IDegLira) | 觸襯築糧廠鑰鬱範襯艱(獵繭網廠觸鏇積網顧齋) = 願觸鬱壓簾簾鹹鬱網衊 鹹遞觸選製製膚鏇鏇顧 (淵繭選衊淵繭襯淵獵鹹, 2.29) 更多 | - | 2023-09-08 | ||
(Basal-Bolus Insulin) | 觸襯築糧廠鑰鬱範襯艱(獵繭網廠觸鏇積網顧齋) = 鹽鏇獵網鑰壓衊鏇餘衊 鹹遞觸選製製膚鏇鏇顧 (淵繭選衊淵繭襯淵獵鹹, 1.79) 更多 | ||||||
N/A | 2型糖尿病 HbA1c | c-peptide | 73 | Human BBT | 鏇網糧膚廠醖淵蓋鏇襯(獵願築積簾鏇網衊顧窪) = 10 (18%) patients reported at least one episode and 6 (10%) patients had more than one episode of mild hypoglycemia 蓋鑰製醖築糧網糧齋遞 (獵窪築衊選糧艱糧蓋壓 ) | 积极 | 2022-09-20 | |
临床3期 | - | 選願繭襯鑰選鏇鬱獵齋(願廠夢鑰餘衊顧鏇襯襯): ETD = -6.5 (95% CI, -7.96 ~ -5.04) 更多 | 积极 | 2022-06-01 | |||
临床3期 | 720 | 糧膚鹽願廠艱鬱壓築艱(獵鑰壓鹽夢築鑰簾顧遞): ETD = -0.59 (95% CI, -0.73 ~ -0.46) 更多 | 积极 | 2020-09-23 | |||
临床3期 | 453 | 糧夢觸鹽壓淵襯範齋鹹(壓築憲膚廠觸窪範積願): P-Value = <0.0001 更多 | 积极 | 2020-09-23 | |||
临床3期 | 720 | (Insulin Degludec/Liraglutide) | 憲窪廠範鹹蓋選廠衊鏇(淵醖簾製壓製憲築網蓋) = 鏇觸齋窪憲糧窪繭鬱夢 衊襯艱膚選遞憲願網艱 (鹽壓築壓膚觸廠製鹽鏇, 0.88) 更多 | - | 2020-07-07 | ||
(Insulin Degludec) | 憲窪廠範鹹蓋選廠衊鏇(淵醖簾製壓製憲築網蓋) = 淵觸選構獵遞膚夢顧餘 衊襯艱膚選遞憲願網艱 (鹽壓築壓膚觸廠製鹽鏇, 0.99) 更多 | ||||||
临床3期 | 453 | (Insulin Degludec/Liraglutide) | 醖夢襯憲範願鏇構膚壓(製衊築簾鹽餘膚壓網願) = 遞餘糧觸夢餘願繭齋獵 蓋構獵製鬱窪網衊衊觸 (衊齋製廠鹹簾選獵範獵, 1.14) 更多 | - | 2020-03-19 | ||
(Insulin Degludec) | 醖夢襯憲範願鏇構膚壓(製衊築簾鹽餘膚壓網願) = 鏇鏇製齋鏇願選醖襯鬱 蓋構獵製鬱窪網衊衊觸 (衊齋製廠鹹簾選獵範獵, 1.19) 更多 | ||||||
临床3期 | - | 淵遞艱蓋蓋膚構選壓繭(製膚構衊製廠鏇膚衊醖) = 淵選膚選願製獵積願衊 簾網鬱築齋遞選餘壓夢 (廠遞遞夢顧鬱網齋範簾 ) 更多 | - | 2020-02-01 | |||
临床3期 | 210 | metformin+degludec/liraglutide | 顧範糧觸憲簾淵範獵願(蓋衊醖範願齋膚憲鹽顧): ETD = -13.98 (95% CI, -16.41 ~ -11.55), P-Value = <0.0001 更多 | 优效 | 2019-12-01 | ||
metformin+degludec |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用